Last updated: September 7, 2026
Perflutren is an ultrasound contrast agent used to improve echocardiographic visualization. The U.S. market is led by Lantheus Holdings' Definity and GE HealthCare's Optison. Definity has the stronger commercial position, broader institutional adoption, and greater strategic value to its owner. The market remains protected less by long-lived composition patents than by manufacturing know-how, regulatory familiarity, hospital contracts, physician workflow, and the technical difficulty of reproducing gas-filled microspheres consistently.
The near-term outlook is stable to moderately positive. Demand is tied to echocardiography volume, cardiovascular disease prevalence, reimbursement, and adoption of contrast-enhanced imaging. Generic-entry risk exists but remains limited because perflutren products are complex injectable suspensions rather than conventional small-molecule tablets.
What is perflutren and which drugs contain it?
Perflutren is a fluorinated gas used in injectable microsphere ultrasound contrast agents. The gas is encapsulated in a shell that stabilizes the microsphere in circulation and increases ultrasound backscatter.
| Product |
Active contrast component |
U.S. sponsor or marketer |
Primary use |
| Definity |
Perflutren lipid microsphere |
Lantheus Medical Imaging |
Contrast-enhanced echocardiography |
| Definity RT |
Perflutren lipid microsphere |
Lantheus Medical Imaging |
Contrast-enhanced echocardiography |
| Optison |
Perflutren protein-type A microspheres |
GE HealthCare |
Contrast-enhanced echocardiography |
| Lumason |
Sulfur hexafluoride lipid-type A microspheres |
Bracco |
Ultrasound contrast, including liver and cardiac imaging |
Lumason competes with Definity and Optison in ultrasound contrast but does not contain perflutren. It is therefore a competitive substitute rather than a perflutren product.
Definity received U.S. Food and Drug Administration approval in 2001. Optison was approved earlier, in 1997. Definity's expanded use in patients with suboptimal echocardiograms materially increased its addressable market. The products are administered intravenously and are primarily used when conventional echocardiography does not provide adequate endocardial-border visualization.[1][2]
How large is the perflutren market?
The public market is concentrated and relatively small compared with pharmaceutical categories such as oncology, diabetes, or immunology. No major sponsor consistently reports a standalone global "perflutren market" figure. The most reliable commercial indicators are product disclosures from Lantheus, GE HealthCare, Bracco, hospital utilization, and echocardiography procedure volumes.
The market has several structural characteristics:
- Cardiology is the principal demand center.
- Hospital and outpatient imaging centers account for most use.
- Product choice depends on availability, imaging-platform compatibility, reimbursement, and clinician familiarity.
- Per-unit pricing is higher than for standard diagnostic drugs, but annual treatment frequency is lower.
- Demand is recurring because contrast is used procedure by procedure rather than as a chronic therapy.
Lantheus is the dominant commercial beneficiary of the U.S. perflutren market through Definity. The company has described Definity as one of its core commercial products and has linked growth to increased contrast utilization in echocardiography, sales execution, expanded customer penetration, and continued adoption of contrast-enhanced imaging.[3]
What is the financial trajectory for Definity and perflutren?
Definity's financial trajectory has been favorable, but Lantheus does not always provide a fully transparent standalone revenue series for each product in its public filings. Lantheus reports consolidated revenue across radiopharmaceuticals, oncology imaging, and diagnostic products. Consequently, company-level performance is a directional indicator rather than a pure Definity income statement.
| Period |
Lantheus consolidated revenue trend |
Main commercial drivers |
| 2021 |
Strong growth from the prior year |
Recovery in imaging volumes and PYLARIFY launch |
| 2022 |
Continued expansion |
PYLARIFY growth and sustained Definity demand |
| 2023 |
Approximately $1.3 billion consolidated revenue |
PYLARIFY expansion, Definity utilization, oncology imaging |
| 2024 |
Approximately $1.6 billion consolidated revenue |
Continued radiopharmaceutical growth, Definity contribution, broader commercial scale |
The company has become increasingly dependent on its prostate-specific membrane antigen imaging agent PYLARIFY for growth. That shift does not mean Definity has become strategically unimportant. Definity provides recurring revenue from an established cardiovascular product and diversifies Lantheus away from a single oncology imaging franchise.
The financial profile of perflutren is attractive for four reasons:
- Manufacturing costs are generally lower than the selling price of a specialty injectable.
- The product is administered in institutional settings, which can support purchasing discipline but also produce repeat utilization.
- The product has established clinical utility and a long regulatory history.
- A branded product can retain share after basic composition-patent expiration because a technically credible substitute must satisfy FDA requirements and hospital quality standards.
Key financial risks include hospital budget pressure, reimbursement changes, supply interruptions, procedure-volume declines, and price competition from Optison or sulfur hexafluoride products.
What patents protect Definity and Optison?
The original patent protection for perflutren contrast agents is largely mature. Early composition, microsphere, shell, and manufacturing patents were filed in the 1990s and early 2000s. Many of those patents have expired or reached the end of their ordinary U.S. terms.
The current protection profile is therefore more layered than a single blocking composition patent.
Definity patent and exclusivity layers
Potential protection categories include:
- Lipid-shell composition
- Gas encapsulation and microsphere stability
- Manufacturing and activation methods
- Vial configuration and storage
- Administration protocols
- Use in technically difficult echocardiographic studies
- Product-specific labeling and safety controls
Definity's commercial protection is strengthened by its long approval history, established manufacturing process, and institutional familiarity. Those factors are commercially important even when foundational patents are no longer enforceable.
The relevant FDA product is Definity, NDA 021064. Definity RT is a later presentation designed to reduce preparation requirements relative to the original product format. Formulation and presentation changes can support patent filings or regulatory differentiation, but they do not necessarily create a complete barrier to an equivalent perflutren product.
Optison patent and exclusivity layers
Optison uses a protein shell rather than the lipid shell used by Definity. That creates a different formulation and manufacturing profile. Its protection is based primarily on product-specific formulation, process, and regulatory history rather than a broad, unexpired monopoly over perflutren as a chemical entity.
The different shell technologies matter competitively. A company seeking to enter the market must reproduce not only the perflutren gas but also the particle-size distribution, shell properties, stability, sterility, dose delivery, and acoustic performance.
What is the Orange Book status of perflutren products?
Definity and Optison are approved prescription products listed in FDA drug databases. Orange Book analysis should distinguish between approved drug products, listed patents, and enforceable market exclusivity.
| Issue |
Definity |
Optison |
| FDA-approved prescription product |
Yes |
Yes |
| Active ingredient |
Perflutren lipid microsphere |
Perflutren protein-type A microspheres |
| Conventional small-molecule product |
No |
No |
| Biologic requiring biosimilar pathway |
No |
No |
| Likely generic pathway |
ANDA or 505(b)(2), depending on equivalence and formulation |
ANDA or 505(b)(2), depending on equivalence and formulation |
| Principal barrier |
Complex microsphere formulation and manufacturing |
Complex microsphere formulation and manufacturing |
| Foundational patent position |
Mature |
Mature |
An Orange Book listing does not by itself establish that a listed patent blocks all competitors. The practical question is whether a proposed product can demonstrate pharmaceutical equivalence, bioequivalence where applicable, comparable imaging performance, and acceptable manufacturing controls.
When does perflutren lose exclusivity?
Perflutren has already lost the type of exclusivity associated with a newly approved chemical entity. Definity was approved in 2001, and Optison was approved in 1997. Their initial regulatory exclusivity periods have long ended.
That does not imply immediate generic substitution. The remaining commercial barriers are:
- Complex product characterization
- Microsphere-size and concentration controls
- Sterility and container-closure requirements
- Activation and handling procedures
- In-use stability
- Imaging-performance comparability
- FDA review of clinical and analytical evidence
- Hospital formulary and purchasing adoption
For a standard oral generic, patent expiry often produces rapid competition. For an injectable ultrasound contrast agent, the timing can be materially later because regulatory development and manufacturing validation are more demanding.
Are there Paragraph IV challenges to Definity or Optison?
No widely established, commercially material Paragraph IV challenge has displaced Definity or Optison in the U.S. market through the publicly documented period covered by this analysis.
A Paragraph IV filing would require an applicant to assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The more important entry question may be whether the proposed product can qualify for an ANDA at all. If the formulation, shell technology, particle properties, or clinical performance differ materially, an applicant may need a 505(b)(2) application rather than a conventional ANDA.
A 505(b)(2) entrant could rely partly on existing safety and efficacy information while developing a differentiated formulation or presentation. That route can reduce some development costs but may leave the entrant exposed to additional clinical, patent, and regulatory disputes.
Is there biosimilar risk for perflutren?
Perflutren does not present conventional biosimilar risk. Definity and Optison are drug products, not therapeutic biologics such as monoclonal antibodies, recombinant proteins, or cell therapies. FDA competition would generally proceed through the generic-drug or 505(b)(2) framework rather than the Public Health Service Act biosimilar pathway.
The more relevant risk is complex-generic or follow-on injectable competition. Such an entrant may attempt to show that the product has equivalent active ingredients and sufficiently comparable performance. FDA's treatment of complex drug products can require extensive analytical characterization and may involve product-specific guidance.
What formulations are protected by perflutren patents?
The main formulation distinction is the microsphere shell.
Definity
Definity uses perflutren encapsulated in a lipid shell. Product performance depends on the lipid composition, gas loading, particle-size distribution, concentration, vial presentation, and activation process.
Optison
Optison uses perflutren in protein-type A microspheres. The protein shell and manufacturing process distinguish it from Definity and create a separate technical pathway for follow-on development.
Definity RT
Definity RT is a presentation and handling evolution of the Definity franchise. Its commercial value is linked to workflow convenience, preparation requirements, and integration into high-volume echocardiography operations.
These differences reduce the likelihood that a single follow-on product will automatically substitute for every incumbent. An entrant may be equivalent to one formulation while remaining technically or clinically distinct from another.
Which companies are challenging or competing with perflutren?
The competitive landscape has three principal companies.
| Company |
Product |
Competitive position |
| Lantheus Holdings |
Definity and Definity RT |
Market leader in perflutren lipid microspheres |
| GE HealthCare |
Optison |
Established alternative with a different shell technology |
| Bracco |
Lumason |
Non-perflutren ultrasound contrast competitor using sulfur hexafluoride |
The most credible near-term competitive pressure comes from established contrast-agent companies and specialized injectable-drug manufacturers. A new entrant would need commercial access to cardiology practices, validated sterile manufacturing, reliable distribution, and a regulatory strategy that addresses complex microsphere equivalence.
What patent litigation affects perflutren?
Perflutren has not generated the level of recurring headline litigation associated with blockbuster oncology or immunology products. The primary legal exposure is more likely to arise from:
- Patent disputes involving formulation or manufacturing methods
- ANDA or 505(b)(2) filings
- Patent-term and Orange Book listing disputes
- Trade-secret claims involving microsphere production
- Contract disputes with hospital distributors or manufacturing partners
- Product-liability claims involving rare hypersensitivity or cardiopulmonary events
The absence of major public litigation does not eliminate patent risk. It indicates that commercial entry has not yet produced a sustained, high-value patent contest comparable to those seen in large chronic-care markets.
How does Definity compare with Optison and Lumason?
| Factor |
Definity |
Optison |
Lumason |
| Active gas |
Perflutren |
Perflutren |
Sulfur hexafluoride |
| Shell |
Lipid |
Protein |
Lipid |
| Main sponsor |
Lantheus |
GE HealthCare |
Bracco |
| U.S. approval history |
2001 |
1997 |
2014 |
| Core use |
Echocardiography |
Echocardiography |
Cardiac, liver, and other ultrasound imaging |
| Commercial scale |
Highest among perflutren products |
Smaller established position |
Broad ultrasound-contrast competitor |
| Main barrier to substitution |
Formulation and workflow |
Formulation and workflow |
Different active gas and clinical positioning |
Definity has the strongest commercial momentum. Lumason has a broader imaging profile in some markets, while Optison retains value as an established cardiac contrast option.
What generic launch scenarios exist for perflutren?
Three entry scenarios are plausible.
Scenario 1: No near-term generic launch
This remains the base case when manufacturing complexity, limited market size, and uncertain return on investment discourage development. Definity and Optison retain pricing power, although hospital purchasing organizations can still negotiate discounts.
Scenario 2: A 505(b)(2) follow-on product
A sponsor could develop a modified shell, vial, concentration, or administration system. This pathway may create a differentiated product rather than a direct generic substitute. The entrant could initially target hospitals seeking lower cost or improved workflow.
Scenario 3: An ANDA-based complex generic
A direct generic would seek pharmaceutical equivalence to an existing product. The largest technical hurdles would be particle characterization, stability, sterility, dose uniformity, and demonstration of equivalent imaging performance. Even after approval, adoption could be gradual because hospitals may maintain multiple products or require local validation.
How strong is the perflutren patent estate?
The patent estate is moderate to weak as a pure exclusionary right and stronger as a commercial barrier.
Foundational composition patents are old. The remaining strength lies in narrower formulation, process, presentation, and use patents, combined with manufacturing know-how and regulatory history. This means a competitor may be able to design around individual patents but still face a costly development program.
For valuation purposes, Definity should be treated as a mature specialty product with durable franchise characteristics, not as a product protected by a single long-dated patent. Its value depends on continued utilization, supply reliability, clinical acceptance, and the timing of complex-generic entry.
What revenue exposure does perflutren create for Lantheus?
Perflutren exposure gives Lantheus a recurring cardiovascular imaging revenue stream. The product also provides portfolio balance as the company expands in radiopharmaceuticals.
The principal exposure is not an abrupt patent cliff. It is a gradual erosion risk arising from:
- New ultrasound contrast products
- Hospital price negotiations
- Reduced echocardiography volume
- Competitor supply reliability
- A successful complex-generic launch
- Shifts toward alternative imaging methods
- Changes in reimbursement or contrast-use policy
Lantheus' larger financial sensitivity currently comes from the performance of its broader imaging portfolio, especially PYLARIFY. Definity remains a valuable cash-generating asset, but it is less likely to determine the entire company's trajectory than it was before the expansion of Lantheus' radiopharmaceutical business.
Key Takeaways
- Definity is the leading U.S. perflutren product and the main commercial asset in the category.
- Optison is an established alternative with a different protein-microsphere formulation.
- Lumason competes in ultrasound contrast but contains sulfur hexafluoride rather than perflutren.
- Initial regulatory exclusivity and foundational patent protection have expired.
- No conventional biosimilar pathway applies.
- Generic-entry risk is limited by microsphere formulation, sterile manufacturing, analytical characterization, and clinical-performance requirements.
- The most likely competitive pathway is a complex generic or 505(b)(2) product, not a routine oral-style ANDA.
- Definity's financial value comes from recurring institutional use and manufacturing know-how rather than a long-dated composition patent.
- Lantheus' consolidated growth is increasingly driven by radiopharmaceuticals, while Definity provides a mature and strategically important cardiovascular revenue base.
- The principal risk is gradual price and share erosion, not an immediate patent cliff.
FAQs
Is perflutren the same as Definity?
No. Perflutren is the gas or active contrast component. Definity is a branded injectable product that encapsulates perflutren in lipid microspheres.
Can a pharmacy substitute Optison for Definity?
Not automatically. The products contain perflutren but use different microsphere shells and are separately approved products. Institutional substitution depends on FDA labeling, hospital policy, procurement decisions, and clinical workflow.
Does Lumason threaten Definity?
Yes, as a competing ultrasound contrast agent. Lumason does not contain perflutren, but it can compete for cardiac and other ultrasound imaging procedures.
Is Definity protected by orphan-drug exclusivity?
Definity is not generally treated as an orphan-drug exclusivity story. Its market position comes from approval history, formulation complexity, manufacturing capability, clinical adoption, and commercial execution.
Could a generic perflutren product launch without clinical trials?
A sponsor may seek an ANDA or 505(b)(2) route, but the required evidence depends on the formulation and degree of similarity. Complex microsphere products can require extensive analytical, manufacturing, and comparative performance data.
References
- U.S. Food and Drug Administration. (2001). Definity: New drug application 021064 prescribing information.
- U.S. Food and Drug Administration. (1997). Optison prescribing information.
- Lantheus Holdings, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.
- Lantheus Holdings, Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2014). Lumason prescribing information.
- U.S. Food and Drug Administration. (2024). Draft guidance on ANDAs for complex drug products.
